Medley of Fungal Infections, and Developing Antifungal Resistance: Post COVID
DOI:
https://doi.org/10.37506/1byd7009Keywords:
Covid 19, fungal infection, aspergillosis, mucormycosis, invasive candidiasis, Voriconazole, isuvaconasole, posaconazole, amohotericin BAbstract
The Covid 19 pandemic has brought a paradigm shift in the incidence of fungal infection. S COV 2 is an RNA virus that causes a serious infection and is associated with many adverse affects involving different organs and systems during its pathogenic cycle in human. Immunocompromised status due to Covid infection especially in vulnerable groups like the elderly and patients with many Co morbidities; and also due to systemic steroid usage in the treatment of the Covid 19 infection has increased the incidence of invasive fungal infection. The most often encountered invasive fungal infection in Covid 19 infected patients and post Covid period are seen due to mucormycosis, aspergillosis, candidiasis. Other infection which are also in increasing trend are caused by pneumocystis Jiroveci, Histoplasma Sp., Cryptococcus Sp. etc. We have made a systematic review from more than 20 articles to know about the most commonly encountered opportunistic fungal infection Post Covid 19 period, the shift in the epidemiology of this fungal infection from the Pre Covid era , Clinical features, diagnosis and treatment. Also we stressed about the anti fungal resistance encountered in the commonly used drugs belonging to the azole group and ecchinocandins etc.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Sudeep Saha, Rima Moni Doley, Udayan Borborah, Juhi Bora, Swdwamshree Boro

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
https://creativecommons.org/licenses/by-nc/2.0/deed.en